"Per capita prescription drug spending in the United States exceeds that in all other countries, largely driven by brand-name drug prices that have been increasing in recent years at rates far beyond the consumer price index." https://t.co/U3SzFYFeqm
If you listen to pharma companies on how to improve health, and tailor science agendas to that end, you get the US. Hugely expensive, lucrative, biomedical, treatment focused, marketing direct to patients. The US system works great for pharma. https://t.co
@ojwouters @JAMANetworkOpen @ihdezdelso @LBerenbrok @UCSDSkaggsSOP The same digs are sold by the same companies overseas for much much less. American consumers are fleeced and many driven into bankruptcy. And only addictive drug cartels get a bad rap. htt
@Arentweallchris @katystoll @Hokieattorney “Although prices are often justified by the high cost of development, there is no evidence of an association between research and development costs and prices; rather, drugs are priced in the US primarily on the b
@DerAlfaSchwabe @marvin_wank Medicare und Medicaid machen nur einen kleinen Prozentsatz des US-Pharmamarktes aus. Medicare Part D übernimmt z.B. nur 25% der Kosten. Üben Sie bitte vorher etwas beim Argumentieren. Und z.B. das lesen: 1) https://t.co/Cny9d
@bnrome @DoniBloomfield @bryanwalsh8 @akesselheim @JAMAInternalMed Excellent! This review from 2005-2016 also cites many studies - The High Cost of Prescription Drugs in the United states- Origins and Prospects for Reform @akesselheim @AmeetSarpatwari @JAM
@jilevin "High drug prices are the result of the approach the United States has taken to granting government-protected monopolies to drug manufacturers, combined with coverage requirements imposed on government-funded drug benefits." JAMA. 2016 Aug 23-30
@JimAndrakakis @U_dioica Δεν υπαρχουν evidence για association between υψηλα κοστη κ R&D develolment. H πηγη σας ειναι αναξιοπιστη. Παρακαλω οπως διαβασετε αξιοπιστες πηγες. Υψηλες τιμες ειναι γιατι υπαρχει εμας ειδος μονοπωλιου προς τις φαρμακευτικες
@jilevin Or maybe, just maybe, the government could stop granting monopolies to drug companies... https://t.co/LwGlSLjn9W
Agreed!
@HollyLynchez @DusetzinaS @RESachs @contirena1 It's already 5 years old, alas, but this one is great, and has worked well for me in the classroom https://t.co/jmoUxMhwnk
@SenSanders Stop letting the FDA grant monopolies on drugs to pharmaceutical companies, Bernard. https://t.co/5mhZVJ0524 Negotiation will never be as effective as market competition.
@lefty_old @newbury_eric https://t.co/5mhZVJ0524 What else you got?
@HowardYangMD @BharatKumarMD @ACRheum @ACRheumDC Sadly, situation only worse after past 5 years... The High Cost of Prescription Drugs in the United States https://t.co/CfCSuUbXBi via @JAMA_current part of @JAMANetwork
@jakep316 @realityman19 @TheSassyOG @CNN Last time I do your homework for you. Like I said. You don't bother to look. Point made again. https://t.co/ABnH2etQeW
The “pay for delay” strategy is discussed in this excellent review of prescription drug prices. https://t.co/vNQ6ZsXcqx https://t.co/9BK0S1vg7S
bestie monopolies aren’t specific to regulated capitalism and the monetary profit motive is the root of the things said in the paper... https://t.co/BOqZsNdHEu
In fact, the whole thread is a sea of misidentified and misattributed quotes. @GroveCtyCollege doesn't appear to be doing a very good job of either education or instilling Christian values. https://t.co/N4GsrhOVw2
Government gives drug companies the ability to be predatory on diabetics -- "High drug prices are the result of the approach the United States has taken to granting government-protected monopolies to drug manufacturers" - Harvard Med. School https://t.co/
@el_sabawi @akesselheim A few references for those insights via @PORTAL_Research: (1) https://t.co/QoqLUHOVmf (2) https://t.co/y7C3oIHOy4 (3) https://t.co/ySOHo9RVqj
RT @donahuejm: Costs of prescription drugs are the highest in the world! In most modern democracies with healthcare the costs of drugs are…
Great Abstract with Full Text available: "The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform" | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network https://t.co/eUGGyDM6gg
@afneil This excellent paper by @akesselheim addresses both that point and the role of patent protection in the US system in holding generics away from market for longer. It is really a tour de force of this issue in the US https://t.co/U0mmI22nPl
2 million... dollars. https://t.co/4U94TQCJMY
@Flyhalf_Zach @jarbizzle https://t.co/UEWFu6Sahg that's an article that shows that Americans spend over double what other industrialized nations. Its findings show that the main reason for the exorbitant prices are due to the monopolies that the us govern
@TotalBuzzKit @prestonjbyrne @Jason Lots of research already. See JAMA https://t.co/E2qXQziNh9 peer reviewed meta study. Their conclusion is instructive and it is worth reading the full article. "High drug prices are the result of the approach the Unite
Relatively recent paper related TJ costs of prescription medications in the US. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network https://t.co/TbZ9waS3DW
@jilevin If the government didn't grant monopolies..."The most important factor that allows manufacturers to set high drug prices is market exclusivity, protected by monopoly rights awarded upon Food and Drug Administration approval and by patents". http
@RepAOC @OversightDems @RepCummings @AyannaPressley "The most important factor that allows manufacturers to set high drug prices is market exclusivity, protected by monopoly rights awarded upon Food and Drug Administration..." https://t.co/7g0ncECE2n
RT @PORTAL_Research: House @OversightDems @GOPoversight Committee: Also see 2016 @JAMA_current article by @PORTAL_Research @akesselheim, #…
RT @PORTAL_Research: .@SenateFinance Committee: Also see 2016 @JAMA_current article by @PORTAL_Research @akesselheim, #JerryAvorn & @Ameet…
.@SenateFinance Committee: Also see 2016 @JAMA_current article by @PORTAL_Research @akesselheim, #JerryAvorn & @AmeetSarpatwari on The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform https://t.co/nddRXMWyXC https
RT @PORTAL_Research: House @OversightDems @GOPoversight Committee: Also see 2016 @JAMA_current article by @PORTAL_Research @akesselheim, #…
House @OversightDems @GOPoversight Committee: Also see 2016 @JAMA_current article by @PORTAL_Research @akesselheim, #JerryAvorn & @AmeetSarpatwari on The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform https://t.
Brand-Name vs Generic Drugs The primary reason for increasing drug spending is... https://t.co/H8pHLm5RIA
Medicare pays for 29% of our the nation’s prescription drug expenditure, but is barred from negotiating lower prices. This article is quite good: https://t.co/E8BkMzVDd7
RT @JerryBuchko: "... there is no evidence of an association between research and development costs and prices; rather, prescription drugs…
@miloforever4 @divnnvx @DeluxeAnchorX69 @dinaa_farinaa "Although prices are often justified by the high cost of drug development, there is no evidence of an association between research and development costs and prices" https://t.co/hMgVQGKpNL
RT @PORTAL_Research: The @FTC also cited a 2016 @JAMA_current Special Communication from @PORTAL_Research: The High Cost of Prescription D…
RT @LondonoMd: Criticar es fácil , hacer difícil. Para los que critican la gestión en salud de este gobierno , valdría la pena que se dirig…
RT @LondonoMd: Criticar es fácil , hacer difícil. Para los que critican la gestión en salud de este gobierno , valdría la pena que se dirig…
RT @LondonoMd: Criticar es fácil , hacer difícil. Para los que critican la gestión en salud de este gobierno , valdría la pena que se dirig…
RT @LondonoMd: Criticar es fácil , hacer difícil. Para los que critican la gestión en salud de este gobierno , valdría la pena que se dirig…
RT @LondonoMd: Criticar es fácil , hacer difícil. Para los que critican la gestión en salud de este gobierno , valdría la pena que se dirig…
RT @PORTAL_Research: The @FTC also cited a 2016 @JAMA_current Special Communication from @PORTAL_Research: The High Cost of Prescription D…
RT @PORTAL_Research: The @FTC also cited a 2016 @JAMA_current Special Communication from @PORTAL_Research: The High Cost of Prescription D…
Criticar es fácil , hacer difícil. Para los que critican la gestión en salud de este gobierno , valdría la pena que se dirigieran a información técnica que evita debates fatuos y bizantinos.Gracias @agaviriau
RT @PORTAL_Research: The @FTC also cited a 2016 @JAMA_current Special Communication from @PORTAL_Research: The High Cost of Prescription D…
RT @PORTAL_Research: The @FTC also cited a 2016 @JAMA_current Special Communication from @PORTAL_Research: The High Cost of Prescription D…
RT @PORTAL_Research: The @FTC also cited a 2016 @JAMA_current Special Communication from @PORTAL_Research: The High Cost of Prescription D…
RT @PORTAL_Research: The @FTC also cited a 2016 @JAMA_current Special Communication from @PORTAL_Research: The High Cost of Prescription D…
RT @PORTAL_Research: The @FTC also cited a 2016 @JAMA_current Special Communication from @PORTAL_Research: The High Cost of Prescription D…
The @FTC also cited a 2016 @JAMA_current Special Communication from @PORTAL_Research: The High Cost of Prescription Drugs in the United States -- Origins and Prospects for Reform https://t.co/6oAO6Thv6w
RT @HealthyMaryland: .@JAMA_current - No evidence of association b/t R&D costs & #Rx prices. Prices are based on what market will bear http…
.@JAMA_current - No evidence of association b/t R&D costs & #Rx prices. Prices are based on what market will bear https://t.co/72tPziOcNS
RT @PORTAL_Research: See @PORTAL_Research in @JAMA_current from 2016 on Origins and Prospects for Reform: https://t.co/LLjAcEGEq7 #policyet…
See @PORTAL_Research in @JAMA_current from 2016 on Origins and Prospects for Reform: https://t.co/LLjAcEGEq7 #policyethx https://t.co/nJYPd1VUe8
RT @HealthyMaryland: .@JAMA_current - No evidence of association b/t R&D costs & #Rx prices. Prices are based on what market will bear http…
RT @HealthyMaryland: .@JAMA_current - No evidence of association b/t R&D costs & #Rx prices. Prices are based on what market will bear http…
WHAT. https://t.co/LDQrJp7HNL
.@JAMA_current - No evidence of association b/t R&D costs & #Rx prices. Prices are based on what market will bear https://t.co/72tPziwBpi
.@JAMA_current - No evidence of association b/t R&D costs & #Rx prices. Prices are based on what market will bear https://t.co/72tPziOcNS
The High Cost of Prescription Drugs in the United States #WHYEXTRA #hpm18 @JAMA https://t.co/UfuItRFimW
.@JAMA_current - No evidence of association b/t R&D costs & #Rx prices. Prices are based on what market will bear https://t.co/72tPziOcNS
.@JAMA_current - No evidence of association b/t R&D costs & #Rx prices. Prices are based on what market will bear https://t.co/72tPziOcNS
Rereading the @JAMA_current “no evidence of an association between research and development costs and prices; rather, prescription drugs are priced in the United States primarily on the basis of what the market will bear” https://t.co/lnoThFoWTU
The High Cost of #Prescription #Drugs in the United States https://t.co/6tfmblZR0N
@WSJ Although companies cite R&D costs as one of the reasons behind the elevated price of pharmaceutical drugs in the U.S., truth has more to do with government granting monopoly rights to corporations to turn grandma's cancer treatment into profit. h
RT @InvestorSwan: @barttels2 Don’t remember reading this JAma article cited in @matthewherper article. Insightful. https://t.co/0gARnPIrnu…
RT @HealthyMaryland: .@JAMA_current - No evidence of association b/t R&D costs & #Rx prices. Prices are based on what market will bear http…
RT @HealthyMaryland: .@JAMA_current - No evidence of association b/t R&D costs & #Rx prices. Prices are based on what market will bear http…
.@JAMA_current - No evidence of association b/t R&D costs & #Rx prices. Prices are based on what market will bear https://t.co/72tPziOcNS
The High Cost of Prescription Drugs in the United States https://t.co/BC7kfhA8u2 And we wonder why Health Care in the US is a totally mess!
A. S. Kesselheim, J. Avorn, and A. Sarpatwari, “The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform,” @JAMA_current https://t.co/nddRXMWyXC
@JEOsborn1957 @baycitycapital @statnews @theNASEM The key paper, from @akesselheim @AmeetSarpatwari & Jerry Avorn, is here. https://t.co/uBY9vS9Tb0
@0Scalia @eagdvm @drscott_atlanta Here is a nice add to ur thread. https://t.co/mxammzjxBH
Source for the aforementioned stuff: https://t.co/6hZSSnFMcP
@CNN @SWAtlasHoover @FraserInstitute He points out Americans have the fastest "access" to drugs, but fails to mention that we are charged 2x as much https://t.co/8dXjrvud7f 7/x
@thlee411 @thehill Source: https://t.co/SADb8BDdqT
RT @NeurologyTimes: A4: And prices are rising. There is no reason medications in the US should cost more than vitamins! @JAMA_current #P2D…
RT @NeurologyTimes: A4: And prices are rising. There is no reason medications in the US should cost more than vitamins! @JAMA_current #P2D…
RT @NeurologyTimes: A4: And prices are rising. There is no reason medications in the US should cost more than vitamins! @JAMA_current #P2D…
RT @NeurologyTimes: A4: And prices are rising. There is no reason medications in the US should cost more than vitamins! @JAMA_current #P2D…
RT @NeurologyTimes: A4: And prices are rising. There is no reason medications in the US should cost more than vitamins! @JAMA_current #P2D…
RT @NeurologyTimes: A4: And prices are rising. There is no reason medications in the US should cost more than vitamins! @JAMA_current #P2D…
RT @NeurologyTimes: A4: And prices are rising. There is no reason medications in the US should cost more than vitamins! @JAMA_current #P2D…
A4: And prices are rising. There is no reason medications in the US should cost more than vitamins! @JAMA_current #P2DocChat https://t.co/rc1jxHjCZ6
RT @advancedmd: T4 Per capita prescription drug spending in the U.S. is higher than ALL other countries https://t.co/LKY1OxoEE6 #P2DocChat
RT @advancedmd: T4 Per capita prescription drug spending in the U.S. is higher than ALL other countries https://t.co/LKY1OxoEE6 #P2DocChat